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ABBREVIATIONS
ASD Autism spectrum disorder
COSMIN COnsensus-based Standards for
selection of health Measure-
ment INstruments
PROM Patient-reported outcome
measure
AIM To identify and appraise the quality of studies that primarily assessed the measurement
properties of English language versions of multidimensional patient-reported outcome
measures (PROMs) when evaluated with children with neurodisability and to summarize this
evidence.
METHOD MEDLINE, Embase, PsycINFO, CINAHL, AMED, and the National Health Service
Economic Evaluation Database were searched. The methodological quality of the papers was
assessed using the COnsensus-based Standards for selection of health Measurement
INstruments checklist. Evidence of content validity, construct validity, internal consistency,
test–retest reliability, proxy reliability, responsiveness, and precision was extracted and
judged against standardized reference criteria.
RESULTS We identified 48 studies of mostly fair to good methodological quality: 37 papers
for seven generic PROMs (CHIP, CHQ, CQoL, KIDSCREEN, PedsQL, SLSS, and YQOL), seven
papers for two chronic–generic PROMs (DISABKIDS and Neuro-QOL), and four papers for
three preference-based measures (HUI, EQ-5D-Y, and CHSCS-PS).
INTERPRETATION On the basis of this appraisal, the DISABKIDS appears to have more
supportive evidence in samples of children with neurodisability. The overall lack of evidence
for responsiveness and measurement error is a concern when using these instruments to
measure change, or to interpret the findings of studies in which these PROMs have been
used to assess change.
Patient-reported outcome measures (PROMs) assess a
patient’s health at a single point in time, and are collected
through short, self-completed questionnaires. PROMs are
advocated for use in clinical trials;1,2 they are also proposed
as key performance indicators for evaluating health sys-
tems.3 Some PROMs are domain-specific, focusing on a
particular aspect of health, such as behaviour; other instru-
ments are multidimensional with sub-scales that assess var-
ious aspects of health and wellbeing. PROMs can be
condition-specific, designed for use by people with a par-
ticular health problem; or they can be generic and there-
fore appropriate for anyone to report their health; or
chronic–generic, designed for people with any long-term
health conditions. Preference-based measures incorporate a
weighting of scores based on a reference valuation of
health states into a single index score; they are used in eco-
nomic evaluations to assessing cost-effectiveness.2
‘Neurodisability’ is an umbrella term commonly used in
the UK for a range of functional problems of neurological
origin. Previously, we proposed a definition of neurodis-
ability for children that was supported by many profession-
als and parents, and indicated a similar grouping of
conditions in other countries, albeit with different termi-
nology.4 For some applications in neurodisability, a condi-
tion-specific PROM may be preferable if available; for
instance, condition-specific measures exist for cerebral
palsy (CP)5 and epilepsy.6 However, it is also common for
generic PROMs to be utilized in neurodisability, especially
for comparison across conditions or with normative sam-
ples. Individually, many conditions that result in a neu-
rodisability are rare, but when grouped together they are
common. Hence there are situations when it will be expe-
dient for children with neurodisability to be grouped for
research, service evaluation, or audits.
When selecting PROMs for a specific purpose, it is nec-
essary to examine both the construct that is being assessed
and the measurement properties of candidate instruments.7
Mapping of items in PROMs using the International Clas-
sification of Functioning, Disability and Health for Chil-
dren and Youth is useful to understand the content
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assessed by questionnaires.8,9 Measurement properties
should, ideally, have been evaluated in samples representa-
tive of the intended population to determine whether the
instrument is applicable for that population.1 Language
and cultural issues also affect how people interpret and
respond to questions; hence one cannot simply assume that
PROMs perform consistently across languages and cul-
tures.10,11 Therefore, the US Food and Drug Administra-
tion recommends that evidence be provided of the process
used to test measurement properties in the language where
assessments will be made.1
Scale development methodology has evolved in recent
years and approaches using item response theory are more
commonly utilized; such approaches use mathematical
models to examine responses to individual items in ques-
tionnaires and offer better scale precision.12 Methods for
appraising the evidence of psychometric performance on
measures have also become more standardized.13 The
COnsensus-based Standards for selection of health Mea-
surement INstruments (COSMIN) was developed to
enable a standardized assessment of the methodological
quality of research studies evaluating measurement proper-
ties of tools.13,14
In previous papers we documented a systematic review
of generic multidimensional PROMs for children and
young people, in which we mapped the content to the
International Classification of Functioning, Disability and
Health for Children and Youth insofar as it was possible,9
and appraised studies evaluating measurement properties in
general population samples.15 In this study we build upon
that foundation by focusing on evaluations of the PROMs
identified in the previous systematic review where they
have been tested in samples of populations with neurodis-
abilities. In this instance, as the aim was to examine which
instruments could be considered robust for application
across children with neurodisability, we also included
chronic–generic tools. We use the word ‘PROM’ to refer
to the group of questionnaires (different versions according
to age group, length, or responder) of a certain instrument;
we use the word ‘questionnaire’ to refer to a specific ver-
sion of an instrument. A list of the PROMs, the different
types of questionnaires, and full names is presented in
Table I.
METHOD
Search strategy
Candidate generic PROMs were identified and catalogued
as part of a previous systematic review.9 In addition,
chronic–generic PROMs were included as they could be
used across neurodisability conditions; three eligible
chronic–generic tools were identified in our broader
research programme (Disabkids, Functional Disability
Index, Neuro-QoL). For this review, three groups of
search terms were combined: the names of the PROMs
and their synonyms; terms for children; and terms for neu-
rodisability, for which both free text and medical subject
headings were used.
Searches were conducted on MEDLINE (including
in-process and other non-indexed citations), Embase, Psy-
cINFO, and AMED (via OvidSP), CINAHL (via EBSCO-
host), and the National Health Service Economic
Evaluation Database (NHS EED; via the Cochrane
Table I: PROMs (group of questionnaires), the different versions (according to age group, length, or responder), and acronyms
Overall PROM name Acronym questionnaire Full name questionnaire
CHIP CHIP-CE CRF Child Health And Illness Profile – Child Edition Child Report Form
CHIP-CE PRF Child Health And Illness Profile – Child Edition Parent Report Form (45-item)
CHIP-CE PRF Child Health And Illness Profile – Child Edition Parent Report Form (76-item)
CHQ CHQ-PF28 Child Health Questionnaire Parent Short Form
CHQ-PF50 Child Health Questionnaire Parent Long Form
CHQ-CF87 Child Health Questionnaire Child Form (87-item)
CHSCS-PS CHSCS-PS Comprehensive Health Status Classification System – Preschool
CQoL CQoL Child Quality of Life Questionnaire
DISABKIDS DISABKIDS DCGM-37 DISABKIDS Chronic Generic Measure – long form
DISABKIDS Smileys-6 DISABKIDS Smiley Measure
EQ-5D-Y EQ-5D-Y EuroQol 5D Youth
HUI HUI2 Health Utilities Index 2
HUI3 Health Utilities Index 3
KIDSCREEN KIDSCREEN-52 KIDSCREEN-52
KIDSCREEN-10 KIDSCREEN-10
Neuro-QOL Neuro-QOL Neurology Quality of Life Measurement System
PedsQL PedsQL Infant Scales Pediatric Quality Of Life Inventory Trade Mark 4.0 – Infant Scales
PedsQL Pediatric Quality Of Life Inventory Trade Mark 4.0 – Generic Core Scales
PedsQL SF15 Generic Core Scales Pediatric Quality Of Life Inventory Trade Mark 4.0 – Short Form 15
SLSS SLSS Student Life Satisfaction Scale
BMSLSS Brief Multi-dimensional Student Life Satisfaction Scale
YQoL YQoL-S Youth Quality of Life instrument – Surveillance version
YQoL-R Youth Quality of Life instrument – Research version
What this paper adds
• PROMs mostly evaluated in children with CP, epilepsy, ADHD, ASD, and
traumatic brain injury.
• Variable methodological quality of studies; improved quality in more recent
evaluations.
• Evidence lacking for instruments to assess meaningful changes in health.
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Library). No date restriction was applied. The searches
were run between 12 and 25 September 2012 and updated
on 30 July 2014. Forward (checking if key papers had been
cited) and backward (checking reference lists) citation chas-
ing was performed for key references to ensure that all rel-
evant literature was retrieved. The electronic search
strategy designed for MEDLINE and translated for the
other databases is presented in Appendix S1 (online sup-
porting information).
Inclusion and exclusion criteria
Articles were selected when written in English and report-
ing on a study that was (1) specifically designed to evaluate
the psychometric properties of candidate PROMs using an
English language version of the questionnaire, (2) con-
ducted in a population including at least 10% children up
to 18 years old with neurodisability, or mixed chronic con-
ditions including neurodisability, and (3) published in a
peer-reviewed journal. Articles were excluded if (1) the
PROM was used as a criterion standard to test another
instrument, (2) less than 10% of the study population was
younger than 18 years, (3) less than 10% of the study sam-
ple was diagnosed with neurodisability.
Study selection
Titles and abstracts of all unique citations were screened
against the eligibility criteria by two reviewers (AJ and
RG/CM); any disagreements were resolved by discussion.
The full text of any potentially relevant article was
retrieved and screened using the same procedure. A flow-
chart describing the process of study selection can be
found in Figure 1.
Assessment of methodological quality of included articles
For each included paper, the COSMIN checklist was used
to appraise the methodological quality of the study and the
completeness of the report.13 We assessed the methods and
reporting of how the following properties had been tested:
internal consistency, reliability, measurement error, content
validity, structural validity, hypothesis testing, criterion
validity, and responsiveness. Cross-cultural validity was not
examined as the purpose of the work was to inform UK
health services policy where currently only English language
versions are administered. The COSMIN checklist uses a
‘worst score counts’ rating of methodological quality as
excellent, good, fair, or poor based on factors such as ade-
quate sample size and appropriate statistical methods used.16
The checklist was administered by two reviewers (AJ and
CM); discrepancies were resolved by discussion.
Data extraction
For each included paper the following descriptive data
were extracted using a standardized, piloted data extraction
form: first author name and year, name and version of the
instrument (including child or parent version), study aim,
study population (participants’ characteristics including type
of neurodisability and diagnosis), number of participants,
age range, mean age (and standard deviation), and setting
or country where the study was conducted. Data were
extracted by one reviewer (RG/AJ) and a 10% sample was
checked by a second (AJ/CM).
Then, any data on evidence of the measurement proper-
ties of instruments were extracted including content valid-
ity (theoretical framework and/or qualitative research),
construct validity (structural validity concerning how
domain sub-scales were determined for instance using fac-
tor analysis, and hypothesis testing to verify sub-scales
measure the intended construct), internal consistency (in-
cluding domain sub-scales where appropriate), test–retest
reliability, proxy reliability (between child and parent), pre-
cision, and responsiveness (whether the increases/decreases
in scores can be considered robust and exceed measure-
ment error). Data were extracted by one reviewer (RG/AJ)
and checked by a second (AJ/CM); disagreements were
resolved by discussion.
Appraisal of measurement properties and summary of
evidence
Evidence of measurement properties was judged using
standardized reference criteria and thresholds
(Table II).12,17 These data were summarized in a single
rating for each measurement property following methods
commonly used for the presentation of such findings.18,19
To summarize available evidence, we took into account the
following elements (Table III): (1) data extracted from
included studies, with reference to standard criteria
(Table II); (2) the methodological quality of studies (COS-
MIN) and number of studies; and (3) the thoroughness of
testing, giving further weight to any studies that appeared
not to have been conducted by the original developers.20
Two reviewers (AJ and CM) made the judgement through
discussion based on available evidence.
RESULTS
We found 48 papers that report evaluations of measurement
properties of 12 PROMs (see Table IV): 37 papers for seven
generic PROMs (CHIP, CHQ, CQoL, KIDSCREEN,
PedsQL, SLSS and YQOL), seven papers for two chronic–
generic PROMs (DISABKIDS and Neuro QOL), and four
papers for three preference-based measures (HUI, EQ-5D-
Y and CHSCS-PS) (Table IV). Twenty papers described
evaluations of the PedsQL4.0 in various neurodisability
samples, and 11 papers pertained to various versions of the
CHQ. The most common conditions in samples were CP,
epilepsy, attention-deficit–hyperactivity disorder (ADHD),
autism spectrum disorder (ASD), and traumatic brain
injury. The evaluations spanned children in a variety of age
groups from 2 to 18 years old. The evaluations were per-
formed in Canada, USA, Europe, and Australia.
The methodological quality of the included studies was
variable (Table V). Internal consistency, test–retest reliabil-
ity, and construct validity (hypothesis testing) have been
more frequently studied in neurodisability samples; several
studies have examined structural validity; very few studies
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have evaluated responsiveness and measurement error. A
summary appraisal of the evidence for measurement prop-
erties of each PROM is given in Table VI.
The PedsQL has been evaluated with children with a
wide range of neurodisability including CP, ADHD, ASD,
acquired brain injury, neuromuscular, and neuro-oncology
conditions. Although there is supportive evidence for the
structural validity and test–retest reliability of the PedsQL,
there is conflicting evidence for the internal consistency of
the subscales, particularly the school functioning domain,
Papers retrieved for full 
text screening by previous 
systematic review
n=180
Title/abstract screening
n=2386
Papers included in review
n=48
Records identified from  
database searches and 
update searches
n=3806
Duplicates: n=1420
Papers retrieved for full 
text screening
n=86
Excluded:
n=2300
151 papers excluded :a only general 
population included (84), results for 
ND population not reported 
separately (11), clinical non-ND 
population (15), adult population (9), 
non-English speaking sample (24), 
instrument used as gold standard (7), 
review/summary paper (8), wrong 
in strument (2), erratum paper (1), 
preference-based measures valuation 
scaling (4), reports on methodology 
of the study (4); no separate results  
for different versions of the PROM 
(3); evidence on one scale of the 
PROM (2).
58 papers excluded:a 
instrument used as gold 
standard (1), adult population 
(32 ), conference abstract (2), 
clinical non-ND population 
(23 ), therapeutic intervention 
tested (not psychometric 
performance) (1), disability 
(not further specified) (8), 
condition specific PROM (1), 
preference-based measures
valuation scaling (2). 
Papers selected for data extraction
n=28
Papers selected for data extraction
n=38
Duplicates
n=9
Figure 1: PRISMA flowchart describing identification and selection of studies evaluating psychometric performance of PROMs in a neurodisability pop-
ulation. aSome papers were excluded for more than one reason. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses;
PROM, patient-reported outcome measure.
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which scored consistently low (0.45–0.65).21–24 Other
papers reported values of Cronbach’s alpha below 0.7 for
emotional functioning,23 social functioning,25,26 and physi-
cal functioning.22 We found conflicting evidence for preci-
sion; overall floor and ceiling effects were less than 15%
for most scales, except social functioning (up to 36%).21,27
The responsiveness of the PedsQL was assessed in one
poor-quality study, thus a rating was not determined.28
Several studies reported child-proxy reliability, all report-
ing low to moderate agreement (intraclass correlation coef-
ficient 0.10–0.75, with most between 0.20 and 0.60).
Versions of the CHQ have been evaluated with children
with CP, ADHD, acquired brain injury, and epilepsy.
There is supportive evidence for the structural validity of
child and parent report versions of the CHQ and internal
consistency of the child report version. Both parent ver-
sions show poor results for ceiling and floor effects on sev-
eral scales; ceiling effects are found for most of the
individual scales, with scores up to 86% for role and social
functioning.29 One study reports low values of Cronbach’s
alpha for the domains family cohesion, bodily pain role/so-
cial functioning, and role/social limitations of the 28-item
version;25 three studies report conflicting findings for the
50-item version, with one paper reporting supportive evi-
dence for all domains30 and two studies reporting low
alpha scores for general health perceptions and family
impact (emotional and time).29,31 We also found conflict-
ing evidence for the CHQ-PF50 for construct validity and
responsiveness.
The DISABKIDS was developed for and with children
who have chronic health conditions including CP and epi-
lepsy. Supportive evidence from methodologically robust
studies exists for content validity, construct validity, and
internal consistency of the 37-item version, and there is
favourable evidence for structural validity, test–retest relia-
bility, and precision. Evidence did not support child-proxy
reliability. For the 6-item version for younger children,
evidence supports the content validity, structural validity,
test–retest reliability, but is conflicting for internal consis-
tency, with values of Cronbach’s alpha dropping just below
0.70 for the child version.32
Kidscreen-52 has been evaluated in one study using
Rasch analysis with data from children with CP in coun-
tries across Europe; the findings for the English language
version were reported separately.33 Evidence supports
structural validity, construct validity, and precision of Kid-
screen-52. Supporting evidence was found for internal con-
sistency and test–retest reliability for the 10-item version
in one study of poorer quality, including children with
CP.25
One methodologically robust study evaluated the SLSS
and BMSLSS with adolescents with conditions including
CP, acquired brain injury, and ASD, providing evidence
for construct validity, structural validity, internal consis-
tency, and test–retest reliability.34
Two papers evaluating the CHIP-CE parent report ver-
sion with children with ADHD support structural validity,
construct validity, internal consistency and precision.35,36
Each of the four preference-based measures has been
evaluated in one study. Evidence from hypothesis testing
supports the construct validity of the CHSCS-PS and
HUI3, but was inconsistent for the EQ-5D-Y. The child-
proxy reliability of the HUI2 was not rated as the study
was of poor quality.
Table II: Appraisal of psychometric properties and indicative criteria
Psychometric
property Indicative criteria
Content validity Clear conceptual framework consistent with
stated purpose of measurement.
Qualitative research with potential respondents
Construct
validity
Structural validity from factor analysis.
Post-hoc tests of unidimensionality by Rasch
analysis.
Hypothesis testing, with a priori hypotheses
about direction and magnitude of expected
effect sizes.
Tests for differential item and scale functioning
between sex, age groups, and different
diagnoses
Reproducibility Test–retest reliability: intraclass correlation
coefficient >0.7 adequate, >0.9 excellent.
Proxy-reliability: child- and parent-reported
reliability intraclass correlation coefficient >0.7
Internal
consistency
Cronbach’s alpha coefficient >0.7 and <0.9
Precision Assessment of measurement error; floor or
ceiling effects <15%; evidence provided by Rasch
analysis and/or interval level scaling
Responsiveness Longitudinal data about change in scores with
reference to hypotheses, measurement error,
and minimal important difference
Table III: Indices for summarizing appraising psychometric properties of
PROMs
Rating Definition
0 Not reported No studies found that evaluate this
measurement property
? Not clearly
determined
Studies were rated poor
methodological quality; results not
considered robust
 Evidence not in
favour
Studies were rated good or
excellent methodological quality;
results did not meet standard
criteria for this property
+/ Conflicting
evidence
Studies were rated fair, good, or
excellent methodological quality;
results did not consistently meet
standard criteria for this property,
e.g. not for all domain scales
+ Some evidence in
favour
Studies were rated fair or good
methodological quality; standard
criteria were met for the property
++ Some good
evidence in favour
Studies were rated good or
excellent methodological quality;
standard criteria were met or
exceeded
+++ Good evidence in
favour
Studies were rated good or
excellent methodological quality;
standard criteria were exceeded,
results have been replicated
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The CQoL was developed with children with intellec-
tual disability, chronic physical disorders, and psychiatric
disorders, and parents. The study reporting the develop-
ment and preliminary testing provides supportive evidence
for content validity; internal validity and test–retest relia-
bility could not be determined as these elements of the
study were of poor quality.
The YQOL was developed for and with children with
disabilities. However, the study reporting on the content
validity of the instrument does not state which conditions
were included.37 A companion paper reports supportive
evidence on structural and construct validity, and internal
consistency in a study of moderate quality, including chil-
dren with ADHD or mobility disability.
We identified three papers reporting on the develop-
ment and initial testing of the Neuro-QOL; two papers
report the same data.38,39 Epilepsy and muscular dystrophy
were selected as conditions for test development of the
paediatric Neuro-QOL item pool. The content validity,
reported in three papers, was rated as good. Domains were
identified through a literature review, expert interviews,
parent and carer focus groups, and keyword search.39,40
Cognitive interviews were conducted with children aged 10
to 18 years to ensure appropriate understanding and liter-
acy levels.38 Other measurement properties were not rated
owing to the poor quality of the studies.
DISCUSSION
This review identified 12 multidimensional PROMs, with
18 versions of questionnaires, that have been evaluated
with children with various neurodisability conditions,
including CP, ADHD, ASD, epilepsy, acquired brain
injury, neuromuscular and neuro-oncology conditions. The
PedsQL and CHQ have been evaluated more than other
instruments, though some of the evidence undermines con-
fidence in their ability to produce robust measurement. On
the basis of this appraisal, the DISABKIDS appears to have
more evidence to support its measurement properties in
samples of children with neurodisability. None of the
PROMs has been evaluated comprehensively across all rel-
evant measurement properties, with responsiveness and
measurement error being the least studied.
The paucity of evidence available for the properties of
responsiveness and measurement error should be a concern
for anyone wishing to use the instruments to measure
change, or for those seeking to interpret the findings of
studies in which these PROMs have been used to assess
change. This gap needs to be evaluated in paediatric popu-
lations with neurodisability to inform decisions about what
constitutes meaningful change scores. Changes in scores
may be statistically significant, especially in large samples,
but may not be clinically important. Indices such as the
minimal clinically important difference is the mean change
in score reported by the respondents who indicate that
they had noticed some small change.41 The minimal clini-
cally important difference has been evaluated for the
PedsQL in a sample of children with diabetes;42 neverthe-
less one cannot necessarily assume this difference will be
the same for children with neurodisability conditions.
Other ways to address the lack of evidence for responsive-
ness include the minimum detectable change, which is an
indication of the amount of change required to have confi-
dence that any observed change is beyond measurement
error; a common standard is to use a 90% confidence
level.43 The effect size is calculated by dividing the amount
of change by the standard deviation of the baseline score.44
Revicki et al.45 suggest calculating different indices of min-
imal change, and for these to triangulate towards a range
of values, in which confidence increases with replication.
There appears a dearth of evaluations of the measure-
ment properties of preference-based measures in children
with neurodisability, adding to the lack of evidence for
these instruments in general populations.15 Internal consis-
tency may conflict with the underlying theory of health
Table VI: Summary appraisal of measurement properties in a population with neurodisability
Instrument versiona
Content
validity
Structural
validity
Construct
validity
Internal
consistency
Test–retest
reliability
Proxy
reliability Precision Responsiveness
BMSLSS 0 + + + + 0 0 0
CHIP CE 0 + + + 0 0 + 0
CHQ-CF87 0 + 0 + 0 0 0 0
CHQ-PF28 0 + 0  0 0  0
CHQ-PF50 0 + +/ +/ 0 0  +/
CHSCS-PS 0 0 + 0 0 0 0 0
CQoL ++ 0 0 ? ? 0 0 0
DCGM-37 +++ + ++ ++ +  + 0
DISABKIDS Smileys-6 ++ + 0 +/ + 0 0 0
EQ-5D-Y 0 0 +/ 0 0 0 0 0
HUI2 0 0 0 0 0 ? 0 0
HUI3 0 0 + 0 0 0 0 0
KIDSCREEN-52 0 + ++ 0 0 0 + 0
KIDSCREEN-10 0 0 0 + + 0 0 0
Neuro-QOL + ? 0 ? 0 0 0 0
PedsQL 4.0 0 + ? +/ ++  +/ ?
SLSS 0 + + + + 0 0 0
YQoL 0 + + + 0 0 0 0
aDefinitions of the instruments are presented in Tables I and SI (online supporting information).
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economic instruments,46 but the properties of face, content
and construct validity, and test–retest reliability remain
requisite. Lack of evidence for these measurement proper-
ties undermines confidence in health economic evaluations
based on preference-based measures. We did not examine
the methods used to derive the scaling of the preference-
based measures; the methods for creating the preference
weighting were assumed to produce interval-level measure-
ment.47 As the purpose of preference-based measures is to
quantify the value or strength of preference for health
change, the means for assuming and eliciting preference
values should be critically assessed.46
The information from this review makes it difficult to
recommend a multidimensional PROM for use in paediatric
neurodisability based on measurement properties estab-
lished in relevant conditions. Our review of evaluations of
generic multidimensional PROMs in general population
samples identified 41 potentially eligible PROMs,9 and
identified 126 papers that reported evidence of the measure-
ment properties of 25 PROMs using English-language ver-
sions in general population samples.15 Although robust
evidence was lacking for one or more properties for all
PROMs, there was evidence to support more measurement
properties for the CHIP, Healthy Pathways,48 KIDSC-
REEN, and MSLSS. The CHU-9D49 was the preference-
based measure with greater evidence of adequate measure-
ment properties. Except for the Healthy Pathways and
CHU-9D, these PROMs have been tested with children and
young people affected by neurodisability; the evidence
shows a similar pattern albeit supported by fewer studies.
Most noticeably absent for all these PROMs are studies
examining content validity. Thus these PROMs might be
leading candidates for further testing in groups with neu-
rodisability, particularly the properties of responsiveness
and longitudinal validity. Tests of responsiveness and longi-
tudinal validity assess how scale scores change over time and
whether the direction and magnitude of the changes reflect
what would be expected on the basis of theory determined
in advance, ideally incorporating a comparison with a group
not expected to change. In the absence of evidence of
responsiveness, those selecting PROMs should appraise
whether the aspects of health assessed by tools and the
response options to questions suggest that these are ‘likely’
to change in their specific context for application.
Although PROMs are generally designed for use as
group measures in service evaluations, audits, and research,
there is also growing interest in using them clinically as
individualized measures.50,51 The proposed criterion for
test–retest reliability is more stringent for individualized
use (intraclass correlation coefficient >0.9),17 and such high
levels of stability would need to be demonstrated in paedi-
atric neurodisability.
Aside from the standard measurement properties, there
are several other criteria that apply when selecting a candi-
date PROM. These include appropriateness, acceptability to
potential respondents, and feasibility: for example the bur-
den on respondents and those administering and processing
data.17 We studied the appropriateness of existing generic
and chronic–generic PROMs for children with neurodisabil-
ity by asking whether they cover the more important aspects
of health for this particular group. We sought to identify a
core set of outcomes that could be assessed using PROMs
for these children; that is, outcomes beyond mortality and
morbidity. To this end we performed qualitative research
separately with children and parents,52 a Delphi survey with
health professionals,53 and held a prioritization meeting.54
This work produced a core set of outcomes deemed impor-
tant to children and/or parents that were aspects of health
targeted by National Health Service clinicians. The domains
were communication, emotional wellbeing, pain, sleep,
mobility, self-care, independence, mental health, commu-
nity and social life, behaviour, toileting, and safety. How-
ever, none of the identified PROMs capture all these key
domains. Adding to this the scarce evidence of good overall
psychometric performance for existing measures in a popu-
lation with neurodisability, there could be a place to refine
or develop existing PROMs accordingly.
There are some limitations to this systematic review;
most are a consequence of the strict inclusion criteria.
Neurodisability comprises a vast number of conditions,
and although we included other general descriptions and
MeSH (Medical Subject Headings) terms for developmen-
tal disabilities, we only had three key marker conditions
(CP, autism, and epilepsy) and relevant variations on
neuro-motor, neuropsychiatric, and developmental disabili-
ties. Although we updated searches for evaluation studies
up to 30 July 2014, we did not repeat the systematic search
to identify any new PROMs after September 2012. Hence,
we will not have included any new PROMs published after
this date; however, we are not aware of any such PROMs
that would meet the eligibility criteria.
One of our inclusion criteria was published peer-
reviewed reports of studies that specifically set out to eval-
uate measurement properties of PROMs. Hence, we
excluded papers that might have presented incidental evi-
dence from studies where PROMs were used in observa-
tional or experimental studies. However, information from
studies that were not designed specifically to test measure-
ment properties can be misleading. Studies testing respon-
siveness require testing of some a priori hypothesis in a
longitudinal study, whereas evaluative trials typically test
interventions of unknown effectiveness. Therefore, for
instance, observing no change could be interpreted as
either a blunt, non-responsive measure or an ineffective
intervention, and it is not possible to determine which is
true.55 In addition, we will have omitted any information
that may be contained in manuals, if these data have not
been published in peer-reviewed journals. We justify this
as peer review provides some level of quality assurance to
the evidence being appraised. We included studies with
children and young people with chronic conditions, pro-
viding the samples included neurodisability. Hence, we did
not appraise studies examining PROMs with children with
other conditions (e.g. arthritis or asthma).
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Limiting the review to studies where an English version
of the PROM was administered excluded some PROMs
from further analyses. Two PROMs excluded from this
review that may warrant further investigation are ITQoL
(for infants),56 which was developed in the Netherlands
and for which an English translation is available but no
published studies of this version were found, and the
TNO-AZL (TACQOL, TAPQOL, and TAAQOL).57 If
studies had been included that used versions of question-
naires in languages other than English, then further evi-
dence would have emerged, for instance regarding the
KINDL58 and the plethora of translated versions of the
more popular instruments such as PedsQL. Nevertheless,
psychometric performance cannot be assumed across lan-
guages and cultures;11 therefore, in our view, limiting the
review to evaluations of English-language versions is a rel-
ative strength of it.
There remains much scope for research in evaluating
multidimensional PROMs to measure health outcomes in
paediatric neurodisability, particularly in testing item
invariance across conditions and the responsiveness of
PROM scores to quantify meaningful change that is
beyond measurement error.
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